The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections
Open accessAbstract
OBJECTIVES: Chronic infections of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients are intractable antibiotic targets because of their biofilm mode of growth. We have investigated the biofilm penetration, mechanism of drug release and in vivo antimicrobial activity of a unique nanoscale liposomal formulation of amikacin designed specifically for nebulization and inhaled delivery. METHODS: Penetration of fluorescently labelled liposomes into sputum or P. aeruginosa (PA3064) biofilms was monitored by a filter assay and by epifluorescence or confocal scanning laser microscopy. Amikacin release in vitro and rat lung levels after inhalation of nebulized material were measured by fluorescence polarization immunoassay. A 14 day agar bead model of chronic Pseudomonas lung infection in rats was used to assess the efficacy of liposomal amikacin versus free aminoglycosides in the reduction of bacterial count. RESULTS: Fluorescent liposomes penetrated readily into biofilms and infected mucus, whereas larger (1 microm) fluorescent beads did not. Amikacin release from liposomes was mediated by sputum or Pseudomonas biofilm supernatants. Rhamnolipids were implicated as the major releasing factors in these supernatants, active at one rhamnolipid per several hundred lipids within the liposomes. Inhaled liposomal amikacin was released in a slow, sustained manner in normal rat lungs and was orders of magnitude more efficacious than inhaled free amikacin in infected lungs. CONCLUSIONS: Penetration of biofilm and targeted, sustained release from liposomes can explain the superior in vivo efficacy of inhaled liposomal amikacin versus free drug observed in a 14 day infection model. Inhaled liposomal amikacin may represent an important therapy for chronic lung infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacterial Biofilms: A Common Cause of Persistent Infections
Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999) · Science · doi:10.1126/science.284.5418.1318 · Cited by 12,167
O'Toole, G. A., & Kolter, R. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.00797.x · Cited by 2,537
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms
Singh, P. K., Schaefer, A. L., Parsek, M. R., Moninger, T. O., Welsh, M. J., & Greenberg, E. P. (2000) · Nature · doi:10.1038/35037627 · Cited by 1,519
Aminoglycoside antibiotics induce bacterial biofilm formation
Hoffman, L. R., D'Argenio, D. A., MacCoss, M. J., Zhang, Z., Jones, R. A., & Miller, S. I. (2005) · Nature · doi:10.1038/nature03912 · Cited by 1,321
Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U. E., Cekici, A., Meyer, K. C., Birrer, P., Bellon, G., Berger, J., Weiß, T., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci13870 · Cited by 1,099
Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation
Drenkard, E., & Ausubel, F. M. (2002) · Nature · doi:10.1038/416740a · Cited by 997
Walters, M. C., Roe, F., Bugnicourt, A., Franklin, M. J., & Stewart, P. S. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.317-323.2003 · Cited by 988
Spoering, A. L., & Lewis, K. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.23.6746-6751.2001 · Cited by 902
Rhamnolipid Surfactant Production Affects Biofilm Architecture in Pseudomonas aeruginosa PAO1
Davey, M. E., Caiazza, N. C., & O'Toole, G. A. (2003) · Journal of Bacteriology · doi:10.1128/jb.185.3.1027-1036.2003 · Cited by 804
Cited by
Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections
Makabenta, J. M. V., Nabawy, A., Li, C.-H., Schmidt-Malan, S., Patel, R., & Rotello, V. M. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0420-1 · Cited by 1,397
Nano-Strategies to Fight Multidrug Resistant Bacteria—“A Battle of the Titans”
Baptista, P. V., McCusker, M. P., Carvalho, A., Ferreira, D. A., Mohan, N. M., Martins, M., & Fernandes, A. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01441 · Cited by 881
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
Döring, G., Flume, P., Heijerman, H., & Elborn, J. S. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.10.004 · Cited by 474
Lipid and polymer nanoparticles for drug delivery to bacterial biofilms
Forier, K., Raemdonck, K., De Smedt, S. C., Demeester, J., Coenye, T., & Braeckmans, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.055 · Cited by 464
In vitro and in vivo model systems to study microbial biofilm formation
Coenye, T., & Nelis, H. J. (2010) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2010.08.018 · Cited by 463
Delivery strategies for sustained drug release in the lungs
Loira-Pastoriza, C., Todoroff, J., & Vanbever, R. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.017 · Cited by 393
Caster, J. M., Patel, A. N., Zhang, T., & Wang, A. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1416 · Cited by 380
Recent advances in materials for extended-release antibiotic delivery system
Gao, P., Nie, X., Zou, M., Shi, Y., & Cheng, G. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.58 · Cited by 310
Gao, Y., Wang, J., Chai, M., Li, X., Deng, Y., Jin, Q., & Ji, J. (2020) · ACS Nano · doi:10.1021/acsnano.0c00269 · Cited by 305
Delivery of antibiotics with polymeric particles
Xiong, M.-H., Bao, Y., Yang, X.-Z., Zhu, Y.-H., & Wang, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.02.002 · Cited by 302
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease
Olivier, K. N., Griffith, D. E., Eagle, G., McGinnis, J. P., Micioni, L., Liu, K., Daley, C. L., Winthrop, K. L., Ruoss, S., Addrizzo-Harris, D. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0700oc · Cited by 254
Recent developments in the use of nanoparticles for treatment of biofilms
Han, C., Romero, N., Fischer, S., Dookran, J., Berger, A., & Doiron, A. L. (2017) · Nanotechnology Reviews · doi:10.1515/ntrev-2016-0054 · Cited by 114
Metadata
- Authors
- Meers, P., Neville, M., Malinin, V., Scotto, A. W., Sardaryan, G., Kurumunda, R., Mackinson, C., James, G., Fisher, S., & Perkins, W. R.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-04
- Volume
- 61
- Issue
- 4
- Pages
- 859-868
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2144814819
- Cited by
- 345
- References
- 34
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.